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INCENTIVE FOR MEASLES, MUMPS, AND RUBELLA
VACCINATION
SIR,-Dr Miller and colleagues (Feb 4, p 271) suggest that
education of parents and professionals could bring about full
measles/mumps/rubella vaccination coverage before the child is two
years old. Dr Narayan (Feb 4, p 272) suggests monitoring of
small-area uptakes and giving authority to the immunisation
co-ordinators, in addition to educational campaigns. In England at
least, unit managers possess the necessary authority and they receive
performance-related pay. We ought to consider seriously the offer
of financial incentives to parents willing to present their children for
immunisation. A c 10 voucher could work wonders for uptake. The
risk of contraindications being hidden by a greedy parent could be
reduced by ensuring that the money is linked to attendance at the
clinic, not to insertion of the needle. A pilot trial is called for.
Peterborough Health Authority,
41 Priestgate,
Peterborough PE1 1LN J. K. ANAND
INHERITED DELETION AT DUCHENNE
DYSTROPHY LOCUS IN NORMAL MALE
SiR,-Detection of deletions in dystrophin cDNA is an accurate
method of predicting the inheritance of Duchenne muscular
dystrophy (DMD). 1-3 In a letter in The Lancet in 19874 we described
a case of inheritance of a deletion of the intron probe from the
DXS206 region in a normal male and his affected sibling. We have
now examined this family, using the entire human dystrophin
cDNA, to determine the presence or absence of the exons encoded
within the region of the familial DXS206 deletion besides the
remainder of the gene, to distinguish the normal and affected male
siblings. No family members are missing exons in the 5’ half of the
dystrophin gene, including the DXS206 region. In contrast, the
affected male bears a second distal deletion of two exons in the
region of the gene which recognises deletions in 50% of affected
males. 1
The 5’-specific cDNA clone 9-71 detected all ten exon-
containing Hind III fragments in all family members (fig 1). The
two intron sequences which detect the proximal deletion (XJ 1.1 and
XJlO.I;2 fig 2) define the minimum limits of the familial deletion at
Fig 1-Hybridisation of dystrophin cDNA clone 9-7 to blot of
Hind III DNA.
All exon containing fragments are present in family members tested.
cDNA probes provided by L. Kunkel. Hybndisation and Iabelhng methods
essentially as reported.3
Fig 2-Taq I digested family DNA blotted and probed with probes
from Duchenne region.
Upper two panels are probed with indicated intron-specific probes from
DXS206 region! Both male offspring demonstrate deletions in DXS206
region, whereas only affected offspring carries a deletion recogmsed by distal
44-1 cDNA probe. XJ1.1 and XJ10.1 probes were from P. Ray and R.
Worton.
the proximal end of the dystrophin gene. The closest exons to this
intronic deletion are 7,8 and 9, which are clearly evident in all family
members (fig 1). In the lower panel of fig 2, a distal portion of the
dystrophin cDNA designated 44-1 was used to detect the exons
from the region of high frequency deletion. The affected male (lane
3) carries a deletion of two exons, while all other family members
have these exons present. Using a spectrophotometric method for
determining dosage5 we showed that the mother of the affected male
has no deletions in this region. It may, therefore, be concluded that
this second unique deletion in a region of high-frequency deletion in
DMD patients1 is the DMD mutation in this affected male and not
the DXS206 mutation.
These data illustrate the paradoxes that may arise during carrier
detection and prenatal diagnosis in DMD families. The origin of the
deletion in the DXS206 region in this pedigree must have been
complex, as shown by the absence of hybridisation in two intronic
probes XJ 1.1 and XJ 10. 11 which are believed to be between exons 7
and 8. Since all exons from this region were present (fig 1), it is
assumed that this DXS206 deletion permitted the proper co-linear
expression of these 5’ exons. To confirm this, the presence of all of
the first ten exons in the dystrophin transcript of the two siblings
will need to be examined at the RNA level. Had the DNA from the
normal male been presented for prenatal study with the commonly
available DMD probes, this deletion would have predicted DMD
and the probable pregnancy outcome would have been termination.
When the dystrophin cDNA probes were used the normal and
affected males produced the same results in the DXS206 region.
These males are distinguishable on the basis of what appears to be a
new mutation (a second unique deletion) in the distal portion of the
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affected sibling’s dystrophin gene. Thus, prenatal diagnosis with
intron probes may sometimes yield erroneous diagnoses.
The possibility that the DXS206 deletion in one of the mother’s
X chromosomes may have contributed to the unique second
deletion in the affected male is intriguing. Because daughters of the
unaffected male sibling may inherit this same DSX206 deletion,
genetic counselling must address this potential increased risk of
bearing an affected male.
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YOUNG DYSPEPTIC PATIENTS
SiR,&mdash;Dr Williams and colleagues (Dec 10, p 1349) contribute to
the debate on routine endoscopy in patients with dyspepsia. The
results of their study are reassuring in that the incidence of
malignant disorders in young patients with dyspepsia was low so
that the risk of delaying a diagnosis of cancer by postponing
endoscopy is negligible. However, cancer detection is not the only
reason for endoscopy in dyspeptic patients, whatever their age.
Dyspepsia is a heterogeneous condition, the causes of which
include both peptic ulcer and non-ulcer disease. Non-ulcer
dyspepsia may be related to mucosal alterations (inflammatory
changes, erosions) or to motor abnormalities.’ Treatment must
therefore depend on the pathogenetic factor(s) underlying the
dyspepsia. Endoscopy may "not ultimately change the treatment",
but that merely highlights the fact that many physicians are more
interested in achieving rapid, albeit temporary, symptom relief than
in trying to remove the causes of dyspepsia. We (and others2) do not
subscribe to Williams and colleagues’ advice that young patients
with dyspepsia be treated first with H2-receptor antagonists. The
effect of these drugs on symptoms in non-ulcer dyspepsia is
controversial,3-5 probably because in some studies most of the
patients had motility disorders rather than acid hypersecretion. Also
in some subpopulations of dyspeptic patients, symptom relief by
H2-blockers is seldom associated with improvement of mucosal
alterations. Ranitidine and sucralfate are equally effective in treating
dyspepsia in symptomatic patients with non-erosive gastritis
(symptom relief being faster with the H2-receptor antagonist), but
sucralfate is significantly superior in promoting endoscopic and
histological healing or in improving mucosal inflammatory
changes Dyspeptic patients with erosive duodenitis can find relief
to the same extent with either ranitidine or pirenzepine, but
pirenzepine is significantly more effective in respect of
disappearance of duodenal erosions.’ Thus the indiscriminate use of
Hz-receptor antagonists in patients with dyspepsia of unknown
origin is irrational and endoscopy remains the only way of achieving
the correct diagnosis and identifying the therapy required. It has
been suggested that with non-ulcer dyspepsia cimetidine
responders might be identified by the presence of symptoms
suggestive of reflux oesophagitis,8 but this is yet to be confirmed.
If an attempt to reduce unnecessary endoscopy has to be made,
then antacid prescription for a few days would seem to be more
reasonable.’"’ Although the efficacy of antacids in relieving
dyspeptic symptoms has also been questioned,’ at least they are
cheaper and less potent drugs, with a lower risk from self-
prescribed, long-term use.
Gastroenterology Unit,
Institute of Internal Medicine,
University of Milan,
20122 Milan, Italy MARIO GUSLANDI
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EXCRETION OF PLATINUM INTO BREAST MILK
SIR,-There are few data on the excretion of antineoplastic
agents into milk of lactating patients. Methotrexate,
cyclophosphamide, doxorubicin, and hydroxyurea have been
recovered from breast milk. 1 Egan et al did not find cisplatin in
milk of a patient treated with cisplatin and doxorubicin for ovarian
cancer.3
We have treated a 24-year-old woman who underwent a
caesarean section at 33 weeks’ gestation because of entodermal sinus
tumour of the left ovary. 6 days after delivery she was treated with
cisplatin 30 mg/m2 intravenously over 4 h on days 1-5 with
hyperhydration, etoposide 120 mg/m2 on days 1, 3, and 5, and
bleomycin 30 mg on days 2, 9, and 16. The patient was advised not
to breastfeed her child. On the third chemotherapy day, 30 min
before the cisplatin infusion, breast milk and blood were collected.
Platinum content was measured by atomic absorbtion
spectrometry. The breast milk contained 0 9 mg/l and plasma
0.8 mg/1.
Although most of the platinum in the breast milk is probably
bound to protein, this does not exclude the possibility of harm to the
child. Hegedus et als found that at least some protein-bound
platinum can react with strongly nucleophilic substances. We
therefore think that a mother should not breastfeed while receiving
cisplatin chemotherapy.
Departments of Internal Medicine, Gynaecology,
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University Hospital Groningen,
9713 EZ Groningen, Netherlands
E. G. E. DE VRIES
A. G. J. VAN DER ZEE
D. R. A. UGES
D. TH. SLEIJFER
1 Johns DG, Rutherford LD, Leighton PC, Vogel CL Secretion of methotrexate into
human milk. Am J Obstet Gynecol 1972; 112: 978-80
2. Wiernik PH, Duncan JH Cyclophosphamide in human milk Lancet 1971; i: 912.
3 Egan PC, Costanza ME, Dodian P, Egorin MJ, Buchur NR Doxorubicin and
cisplatin excretion into human milk Cancer Treat Rep 1985, 69: 1387-89
4. Sylvester RK, Lobell M, Teresi ME, Brundage D, Dubowy R Excretion of
hydroxyurea into milk Cancer 1987, 60: 2177-78
5 Hegedus L, va der Vijch WJF, Klein I, Kerpel-Fronius S, Pinedo HM Chemical
reactivity of cisplatin bound to human plasma proteins Cancer Chemother
Pharmacol 1987; 20: 211-12
